Nationwide Children's Hospital and Families of Spinal Muscular Atrophy announce the award of a multi-million dollar cooperative agreement from the NINDS to advance a gene therapy development program for Spinal Muscular Atrophy.

The primary objectives of the study are to further evaluate the safety and plasma pharmacokinetics (PK) of multiple doses of RG3039 in healthy volunteers.

Families of Spinal Muscular Atrophy (FSMA) is dedicated to creating a treatment and cure for Spinal Muscular Atrophy (SMA) by funding and advancing a comprehensive research program

Families of SMA is pleased to announce the award of up to $750,000 for an important new grant to Dr. Brian Kaspar at Nationwide Children's Hospital.

Repligen Corporation (NASDAQ:RGEN) today announced positive results from a Phase 1 study to evaluate the pharmacokinetic (PK) and safety profile of RG3039, a novel small molecule drug candidate for the potential treatment of SMA.

With the 9th Annual Jacob's Run, Walk & Roll Event to be held on April 1st, The Jacob Isaac Rappoport Foundation is aiming to reach the milestone of raising $1,000,000 for Spinal Muscular Atrophy (SMA) Research

Leading New York based trade show exhibit design firm, Skyline Genesis Event Marketing, takes initiative in raising awareness and funds for Spinal Muscular Atrophy (SMA)

"Nutrition Basics: Fostering Health and Growth for Spinal Muscular Atrophy" is Families of SMA's newest release of the SMA Care Series Booklets.

Awards will help develop new approaches for SMA therapies. These new awards encompass $745,000 for the basic research portion of the $3 Million in new research funding that FSMA announced earlier this year.

The new funding awards will be allocated into three distinct research areas: 1)Basic Research to understand the disease, 2)Drug Discovery to develop new SMA therapies, and 3)Clinical Research to provide the means to test new drugs effectively.

First ever clinical trial approved for SMA with a novel drug specifically designed to treat the disease.

The MDA has committed to invest funds in the FSMA Quinazoline Program at Repligen Corporation to assist in advancing the program to an IND filing with the FDA.

Families of SMA announces Request for Proposals (RFP) for new drug programs to develop therapies for Spinal Muscular Atrophy.
FSMA is aiming to fund two new preclinical drug development programs in 2011, with more to follow.

Planet Gift Baskets supports the annual fund raiser for Spinal Muscular Atrophy and family support.

All across the United States volunteers will come together to raise funds for critical SMA research and patient support programs. These events range from the FSMA signature Walk-n-Roll, to golf outings and fun comedy nights.